^
Association details:
| Biomarker: | ERCC2 N238S |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Excerpt:
Patients with muscle invasive or locally advanced urothelial carcinoma and extreme responses to chemotherapy…all ERCC2 non-synonymous somatic mutations occurred in the cisplatin sensitive tumors (P < 0.001; Fisher’s exact test). ERCC2 remained significantly enriched in responders...Supplementary table 5
Secondary therapy:
Chemotherapy
DOI:
10.1158/2159-8290.CD-14-0623
